<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H8B99FBC803E940C7A8CCAC911EA934AD" public-private="public" bill-type="olc"> 
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 2841 IH: Fair Access for Safe and Timely Generics Act of 2015</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-06-18</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code> 
<congress>114th CONGRESS</congress> <session>1st Session</session> 
<legis-num>H. R. 2841</legis-num> 
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber> 
<action> 
<action-date date="20150618">June 18, 2015</action-date> 
<action-desc><sponsor name-id="S001187">Mr. Stivers</sponsor> (for himself, <cosponsor name-id="W000800">Mr. Welch</cosponsor>, <cosponsor name-id="M001180">Mr. McKinley</cosponsor>, <cosponsor name-id="S001145">Ms. Schakowsky</cosponsor>, <cosponsor name-id="R000586">Mr. Renacci</cosponsor>, and <cosponsor name-id="T000462">Mr. Tiberi</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc> 
</action> 
<legis-type>A BILL</legis-type> 
<official-title>To amend the Federal Food, Drug, and Cosmetic Act to ensure that eligible product developers have competitive access to approved drugs and licensed biological products, so as to enable eligible product developers to develop and test new products, and for other purposes.</official-title> 
</form> 
<legis-body id="H4F3EC1D49E204871B671D87A6360C347" style="OLC"> 
<section id="H008609F2F492458B9EB6BBB34A619A97" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Fair Access for Safe and Timely Generics Act of 2015</short-title></quote> or the <quote><short-title>FAST Generics Act of 2015</short-title></quote>.</text></section> <section id="HA774B231454D4887AE16B2C02680B35B"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">The Congress finds the following:</text> 
<paragraph id="H23DA8C39E79D447FA1954F3D27D2E4BD"><enum>(1)</enum><text>Reference product license or approval holders are restricting competitive access to reference products by sponsors seeking to develop drugs, generic drugs, and biosimilars under section 505(b)(2) or 505(j) of the Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(b)(2)</external-xref> and 355(j)) and under section 351(k) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)</external-xref>). These restrictions are deterring and delaying development of drugs, generic drugs and biosimilars by extending lawful patent-based monopolies beyond their lawful patent life.</text></paragraph> <paragraph id="HF16B279F37FE42F1A383C4C95A40C74E"><enum>(2)</enum><text>The enforcement provisions set forth in section 505–1(f)(8) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1(f)(8)</external-xref>) have not been sufficient to prevent anti-competitive practices that interfere with access to reference products which is necessary for the timely development of affordable drugs, generic drugs, and biosimilars.</text></paragraph> 
<paragraph id="HFD04FB09E99A421E9A2D70D0643EB741"><enum>(3)</enum><text>There is not a regulatory structure in place that is sufficient to deter or remedy the anti-competitive harm that results when—</text> <subparagraph id="H0083356EBEFD43A3967430A4A0B6A0DF"><enum>(A)</enum><text>access to reference products is restricted to sponsors developing drugs, generic drugs, or biosimilars in accordance with section 505(b)(2) or 505(j) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(b)(2)</external-xref> or 355(j)), and section 351(k) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)</external-xref>), respectively; or</text></subparagraph> 
<subparagraph id="H3086FF77DF384880B577EE0495EB03FC"><enum>(B)</enum><text display-inline="yes-display-inline">license holders impede the prompt negotiation and development of a single, shared system of elements to assure safe use and supporting agreements under section 505–1(i)(1)(B) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1(i)(1)(B)</external-xref>), on commercially reasonable terms.</text></subparagraph></paragraph> <paragraph id="H3E40E46F155A4FE1BAE2EE8D0EC6245F"><enum>(4)</enum><text>Requiring license holders to comply with requirements for competitive access to their products, and for the negotiation and development of single, shared systems of elements to assure safe use under section 505–1(i)(1)(B) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1(i)(1)(B)</external-xref>), and subjecting license holders to liability for failing to do so, will not impose obligations on the courts that they cannot adequately and reasonably adjudicate.</text></paragraph></section> 
<section id="HB62F37AA24EC4E1185D49AAA0463F7D4"><enum>3.</enum><header>Competitive access to covered products for development purposes</header> 
<subsection id="HC2E958B868AF404ABEBB226376FD350A"><enum>(a)</enum><header>In general</header><text>Chapter V of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351 et seq.</external-xref>) is amended by inserting after section 505–1 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1</external-xref>) the following new section:</text> <quoted-block id="H0962110C926C47C28E559AF1FA8CDB8A" style="OLC"> <section id="HCAF6DB9BD7824E3AA2B4B895F3696F78"><enum>505–2.</enum><header>Competitive access to covered products for development purposes</header> <subsection id="HDC547ED5FB8845A6B97A0C3B7740C358"><enum>(a)</enum><header>Definitions</header><text>In this section:</text> 
<paragraph id="HD0445D306D8F43BCA98E84047FFC1608"><enum>(1)</enum><header>Covered product</header><text display-inline="yes-display-inline">The term <term>covered product</term>—</text> <subparagraph id="HE55D919C0E934B5F890A39D468B139D4"><enum>(A)</enum><text>means—</text> 
<clause id="HE3BC118FE443472A8CA57EE5A6B3E237"><enum>(i)</enum><text>any drug approved under section 505 or biological product licensed under section 351 of the Public Health Service Act;</text></clause> <clause id="HEB438D4DA71541DF93FF7FD891F9A5C0"><enum>(ii)</enum><text>any combination thereof; or</text></clause> 
<clause id="HA945D6B26BA64468AE60233BEB4459DD"><enum>(iii)</enum><text display-inline="yes-display-inline">when reasonably necessary to demonstrate sameness, biosimilarity, or interchangeability for purposes of this section, section 505, or section 351 of the Public Health Service Act (as applicable), any product, including any device, that is marketed or intended for use with such drug or biological product; and</text></clause></subparagraph> <subparagraph id="H6A0DC19122F44F94AB3D3D1A6F7BD0AD"><enum>(B)</enum><text display-inline="yes-display-inline">excludes any drug or biological product which the Secretary has determined to be currently in shortage and that appears on the drug shortage list in effect under section 506E, unless the shortage will not be promptly resolved—</text> 
<clause id="H5CED53DDC9DD48C0A1D80121B7AEFDFC"><enum>(i)</enum><text>as demonstrated by the fact that the drug or biological product has been in shortage for more than 6 months; or</text></clause> <clause id="H69CAD4B66B91442EA7F1D5DFFDECC95F"><enum>(ii)</enum><text>as otherwise determined by the Secretary.</text></clause></subparagraph></paragraph> 
<paragraph id="H75D2681054D046F4AB4DE3D17D399246"><enum>(2)</enum><header>Eligible product developer</header><text display-inline="yes-display-inline">The term <term>eligible product developer</term> means a person that seeks to develop a product for approval pursuant to an application under section 505(b)(2) or 505(j) or for licensing pursuant to an application under section 351(k) of the Public Health Service Act.</text></paragraph> <paragraph id="H7F09AEE09789471D88DA604D547BDF70"><enum>(3)</enum><header>License holder</header><text>The term <term>license holder</term> means the holder of an application approved under section 505(b) or section 505(j) of this Act or under section 351 of the Public Health Service Act for a covered product (including the holder’s agents, wholesalers, distributors, assigns, corporate affiliates, and contractors).</text></paragraph> 
<paragraph id="HB622562EE8C54089AAB93E86D8B655E1"><enum>(4)</enum><header>REMS</header><text>The term <term>REMS</term> means a risk evaluation and mitigation strategy under section 505–1. </text></paragraph> <paragraph id="H499079768ED8474487A3674AC87F0A26"><enum>(5)</enum><header>REMS product</header><text>The term <term>REMS product</term> means a covered product that—</text> 
<subparagraph id="H61E355A990AE4A1586D558FB94131C58"><enum>(A)</enum><text>is subject to a risk evaluation and mitigation strategy under section 505–1; or</text></subparagraph> <subparagraph id="H17D166CD4C264899BB6C87CBE048CC8B"><enum>(B)</enum><text>is deemed under section 909(b) of the Food and Drug Administration Amendments Act of 2007 to have in effect an approved risk evaluation and mitigation strategy under section 505–1.</text></subparagraph></paragraph> 
<paragraph id="H676E3E846592410FAE9CAD7CDEEC99D9"><enum>(6)</enum><header>REMS impacting product distribution</header><text>The term <term>REMS impacting product distribution</term> means a REMS that contains elements to assure safe use that impact the distribution of the product subject to the REMS.</text></paragraph></subsection> <subsection id="H4A3B3E6415F94EE2A09DE243F775392D"><enum>(b)</enum><header>Competitive access to covered products as a condition on approval or licensing</header><text>As a condition of approval or licensure, or continuation or renewal of approval or licensure, of a covered product under section 505 of this Act or section 351 of the Public Health Service Act, respectively, the Secretary shall require that the covered product’s license holder not construe or apply any condition or restriction relating to the sale, resale, or distribution of the covered product, including any condition or restriction adopted, imposed, or enforced as an aspect of a risk evaluation and mitigation strategy, in a way that restricts or has the effect of restricting the supply of such covered product to an eligible product developer for development or testing purposes.</text></subsection> 
<subsection id="H8642DB3527E8492D8E4FA32B202EABD7"><enum>(c)</enum><header>Competitive access for development purposes to products with REMS impacting product distribution</header><text>With respect to a product subject to a REMS impacting product distribution, no aspect of such a REMS shall be construed or applied by the REMS product’s license holder in a way that prohibits or restricts the supply, at commercially reasonable, market-based prices, of such REMS product from the REMS product’s license holder to an eligible product developer with an applicable individual covered product authorization obtained pursuant to subsection (e) for development and testing purposes.</text></subsection> <subsection id="H34D318F574A54B7DAB2487061AC1CDAB"><enum>(d)</enum><header>Single, shared system of elements To assure safe use</header><text display-inline="yes-display-inline">Where an eligible product developer seeks approval of an application under 505(j) referencing a REMS product whose REMS includes elements to assure safe use—</text> 
<paragraph id="H1C84CCD22B3E431598071891984CF5D3"><enum>(1)</enum><text>no license holder shall take any step that impedes—</text> <subparagraph id="HD7F9B0E23C704D1099915D7A61DC9F4E"><enum>(A)</enum><text>the prompt development on commercially reasonable terms of a single, shared system of elements to assure safe use under section 505–1; or</text></subparagraph> 
<subparagraph id="HF332B3093C344CF792CC9EF55755D58A"><enum>(B)</enum><text>the prompt entry on commercially reasonable terms of an eligible product developer into a previously approved system of elements to assure safe use; and</text></subparagraph></paragraph> <paragraph id="HADC3C0C48C074A7D9C11AECC3927E5BA"><enum>(2)</enum><text display-inline="yes-display-inline">license holders shall negotiate in good faith towards the prompt development of (or entry into) a single shared system of elements to assure safe use under section 505–1(i) on commercially reasonable terms.</text></paragraph></subsection> 
<subsection id="H05CA72BCC658497EB9DFF20746881E96"><enum>(e)</enum><header>Procedures for obtaining access to covered products</header> 
<paragraph id="HAF8493942DEF4E739CA654706F56C2FF"><enum>(1)</enum><header>Competitive access to products not subject to REMS impacting product distribution</header><text>Notwithstanding any other provision of law, a license holder that receives a request from an eligible product developer or its agent for sufficient supplies of a covered product (that is not subject to a REMS impacting product distribution) to conduct testing necessary to support an application under section 505(b)(2) or 505(j) or under section 351(k) of the Public Health Service Act (or otherwise meet the requirements for approval of such an application) shall provide to the eligible product developer or its agent the quantity requested within 30 days of receipt of the request at a nondiscriminatory, commercially reasonable, market-based price for which such covered product has been previously sold by the license holder to third parties in the open market.</text></paragraph> <paragraph id="H507D7B684CC846C8B0386BD605B582A7"><enum>(2)</enum><header>Competitive access to products subject to REMS impacting product distribution: individual covered product authorization</header><text>Any eligible product developer may seek an authorization to obtain an individual covered product subject to a REMS impacting product distribution for development and testing purposes by making a written request to the Secretary. Within 120 days of receiving such a request, the Secretary shall, by written notice, issue such authorization for purposes of—</text> 
<subparagraph id="HE55D4C3DB929402DA78020BD76B061AD"><enum>(A)</enum><text>development and testing that does not involve human clinical trials, if the eligible product developer has agreed to comply with any conditions the Secretary determines necessary; or</text></subparagraph> <subparagraph id="H4B34A238A19944C2ABA83BBE6E030C52"><enum>(B)</enum><text>development and testing that involves human clinical trials if the eligible product developer has—</text> 
<clause id="H77E46F328A174A78906F7077454714B2"><enum>(i)</enum><text>submitted a protocol for testing that includes protections that will provide an assurance of safety comparable to the assurance of safety provided by any distribution restrictions governing the approval or licensure of the covered product; or</text></clause> <clause id="H2BBBF292B378461CB0E7606E1C4EC67E"><enum>(ii)</enum><text>otherwise satisfied the Secretary that such protections will be provided.</text></clause></subparagraph></paragraph> 
<paragraph id="HF20F01E7985743478C4899C7ECA2D09A"><enum>(3)</enum> 
<subparagraph id="HB7C5FC369CE54B4AAAB682E2E9ADD538" display-inline="yes-display-inline"><enum>(A)</enum><header>Process for obtaining product pursuant to an authorization</header> 
<clause id="HD5374F0F45894283B330F7ECC386A5BB" indent="up1" commented="no"><enum>(i)</enum><text display-inline="yes-display-inline">An eligible product developer shall be entitled to obtain, from the license holder of a covered product subject to a REMS impacting distribution, sufficient quantities of the covered product for purposes of development and testing necessary to support an application under section 505(b)(2) or 505(j) or under section 351(k) of the Public Health Service Act, or otherwise meet the requirements for approval of such application, if the eligible product developer has obtained an applicable authorization under paragraph (2).</text> </clause> <clause id="H630727CA34C3428EACD669D43AF9960C" indent="up1"><enum>(ii)</enum><text>Each license holder shall publicly designate at least one wholesaler or specialty distributor to receive and fulfill requests for covered products submitted pursuant to paragraph (1) or clause (i) of this paragraph.</text></clause> 
<clause id="H676708C161DE4FE7AA88E6CACA9AA25F" indent="up1"><enum>(iii)</enum><text>An eligible product developer shall initiate its acquisition of a covered product under clause (i) by providing or having its agent provide a written request for specific quantities of such covered product to the license holder.</text></clause></subparagraph> <subparagraph id="H4EAFB43668284552A956CD67BAAF4045" indent="up1" commented="no"><enum>(B)</enum><header>Request contents and response</header><text>A request under subparagraph (A)(iii) shall include a statement regarding the quantity of covered product sought for development or testing purposes, and state that the eligible product developer has an authorization under paragraph (2) to obtain the specific covered product. Within 30 days of receiving such a request, the wholesaler or specialty distributor shall provide the requested quantity of the covered product at a non-discriminatory, commercially reasonable, market-based price for which such covered product has been previously sold by the license holder to third parties in the open market.</text></subparagraph> 
<subparagraph id="H49D438B1879B40AE9D15F4A4FFAB6AEB" indent="up1" commented="no"><enum>(C)</enum><header>Disclosure of information by wholesalers and specialty distributors</header><text>In the event that a request is made to a wholesaler or specialty distributor under this paragraph, the wholesaler or specialty distributor shall not disclose to the license holder of the covered product involved the identity of the eligible product developer, but may disclose to such license holder—</text> <clause id="H0B3BC3A17A6546F89D40337CE903EDEB" commented="no"><enum>(i)</enum><text>the fact that a request has been made;</text></clause> 
<clause id="HF936E2D318C94669ADC5CE9741265C62" commented="no"><enum>(ii)</enum><text>the dates on which the request was made and fulfilled;</text></clause> <clause id="H2E702ECADCDB4E5DB2BE0675E72DFC4A" commented="no"><enum>(iii)</enum><text>the commercial terms on which the request was fulfilled; and</text></clause> 
<clause id="H9B4B121895644EE6B567BC14C7BFBBBA" commented="no"><enum>(iv)</enum><text>the quantity of the covered product furnished by the wholesaler or specialty distributor in compliance with the request.</text></clause></subparagraph> <subparagraph id="H804B7256D3914EDAB28FDCEBC32F8337" indent="up1" commented="no"><enum>(D)</enum><header>Imminent hazard</header><text>At any time, the Secretary may prohibit, limit, or otherwise suspend a transfer of a covered product to an eligible product developer if the Secretary determines that the transfer of such product to the eligible product developer would present an imminent hazard to the public health. In such cases, the Secretary shall specify the basis for the determination, including the specific information available to the Secretary which served as the basis for such determination, and confirm such determination in writing.</text></subparagraph></paragraph></subsection> 
<subsection id="H1DF5CF61211D446DB66FE2015259AC22" commented="no"><enum>(f)</enum><header>Enforcement</header><text display-inline="yes-display-inline"></text> <paragraph id="HB0022A9DA9B54F8FBBE68AA74BE13148" commented="no"><enum>(1)</enum><header>Remedies</header><text>An eligible product developer that is aggrieved by a violation of subsection (b), (c), (d), (e)(1) or (e)(3) by a license holder may sue such license holder in a court of competent jurisdiction for injunctive relief and treble damages (including costs and interest of the kind described in section 4(a) of the Clayton Act (<external-xref legal-doc="usc" parsable-cite="usc/15/15">15 U.S.C. 15(a)</external-xref>)).</text></paragraph> 
<paragraph id="H45C612FF19E14BB7B74AA7CA5F120DDF" commented="no"><enum>(2)</enum><header>Rule of construction</header> 
<subparagraph id="H0890886A6D8B461EABD7E2DA2F998FB1" commented="no"><enum>(A)</enum><header>Preservation of antitrust laws</header><text display-inline="yes-display-inline">Nothing in this Act, or the amendments made by this Act, shall be construed to modify, supersede, or impair the operation of the antitrust laws.</text></subparagraph> <subparagraph id="H37577BC5C50E4DEDB24B79221CF144F9" commented="no"><enum>(B)</enum><header>Definition</header><text>For purposes of paragraph (1), the term <term>antitrust laws</term> shall have the meaning given such term in subsection (a) of the 1st section of the Clayton Act (<external-xref legal-doc="usc" parsable-cite="usc/15/12">15 U.S.C. 12</external-xref>), except that such term shall include section 5 of the Federal Trade Commission Act (<external-xref legal-doc="usc" parsable-cite="usc/15/45">15 U.S.C. 45</external-xref>) to the extent that such subsection applies to unfair methods of competition.</text></subparagraph></paragraph></subsection> 
<subsection id="H70A52BFF18994FA2AF19C60423715F1A" commented="no"><enum>(g)</enum><header>Limitation of liability</header><text display-inline="yes-display-inline">The holder of an approved application or license for a covered product shall not be liable for any claim arising out of an eligible product developer’s failure to follow adequate safeguards to assure safe use of the covered product during development or testing activities conducted under this section.</text></subsection> </section><after-quoted-block>.</after-quoted-block></quoted-block></subsection> <subsection id="H1C24538EA37F4E95A09F6A518092B538"><enum>(b)</enum><header>Waiver of single, shared system requirement</header><text>Section 505–1(i)(1)(B) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1(i)(1)(B)</external-xref>) is amended—</text> 
<paragraph id="HC3E360DFFC004DD39525CD731A8CC90C"><enum>(1)</enum><text>in clause (i), by striking <quote>or</quote> at the end;</text></paragraph> <paragraph id="H0FFA910D30C3404FAA5660FD800E6BBB"><enum>(2)</enum><text>in clause (ii), by striking the period at the end and inserting <quote>; or</quote>; and</text></paragraph> 
<paragraph id="HF93C05CA56594183B3C8DC008327A7E1"><enum>(3)</enum><text>by adding at the end the following:</text> <quoted-block id="H0F5FB3F9F3D74D8F98E00B67CBC7AD40" style="OLC"> <clause id="HB12C5F504A784339B0AC390619E582B7"><enum>(iii)</enum><text>the applicant for an abbreviated new drug application certifies that it attempted in good faith to create or negotiate entry into a single, shared system, but was unable to finalize commercially reasonable terms with the holder of the listed drug within 120 days, and such certification includes a description of the efforts made by the applicant for the abbreviated new drug application to create or negotiate entry into a single, shared system.</text></clause><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection> 
<subsection id="HE35D67D671C64E0FB1669CE53FF9FFC6"><enum>(c)</enum><header>Effective date</header><text>This section and the amendments made by this section shall take effect upon enactment, and shall apply to all approved applications or licenses for a covered product (as defined in section 505–2(a) of the Federal Food, Drug, and Cosmetic Act, as added by this section) regardless of whether those applications or licenses were approved before, on, or after the date of enactment of this Act.</text></subsection></section> </legis-body> </bill> 

